UNC opens first clinical trial of vaccine treatment for advanced breast cancer

June 29, 2000

CHAPEL HILL -- Doctors at the University of North Carolina have opened their first clinical trial of a vaccine treatment for advanced breast cancer.

After more than four years of test tube and animal studies, researchers at UNC Lineberger Comprehensive Cancer Center will find out if intravenous infusions of their genetically engineered protein fragments will stimulate a person's immune cells to recognize and kill breast cancer cells, causing advanced breast tumors to shrink.

"This breast cancer vaccine is not a shot. It's a 'vaccine' because it should work by enhancing the patient's own immune response against their tumor," said Lineberger member Jonathan Serody, MD, associate professor of medicine and microbiology and immunology at UNC-CH School of Medicine.

"This is the first use of a vaccine directed against a modification of a specific part of the HER-2/neu protein found on breast cancer cells," he added. People have tried using engineered proteins in the treatment of melanoma but not for breast cancer." A breast cancer patient from Rochester, New York, is scheduled for her first vaccine infusion Thursday July 6, 2000.

Dr. Serody noted that current treatments, although helpful, do not cure an adequate number of women with advanced breast cancer, in which the disease has spread beyond the breast. "Often women with this disease have responses to treatment, but these are of brief duration and are not durable," he explained." he explained.

At the heart of the new treatment is the dendritic cell, a type of white blood cell that alerts the immune system to the presence of abnormal cellular proteins. The dendritic cells snatch fragments of these proteins and race to the lymph nodes to display them as targets for an immune response. Regiments of killer T-cells then proliferate, seek out and cause the destruction of cells carrying the targeted protein.

Led by Drs. Ed Collins, Jeffrey Frelinger, Roland Tisch and Jonathan Serody, the UNC research team found a way to engineer dendritic cells to target the protein HER2/Neu, which is found in tumors of about one-third of women with breast cancer. To make the vaccine, the team removes progenitor cells -- dendritic cell precursors -- from the patient's blood.

"At any one time, the percentage of dendritic cells in the bloodstream is quite small, maybe one hundredth to one thousandth of the cells in the bloodstream," Dr. Serody explained. "So we need to increase that number initially by giving the person injections of growth factor, which increases the number of immature progenitors in the blood. Then we expand those cells greatly in the lab dish by adding other proteins that allow for dendritic cell growth."

An engineered protein fragment of HER2/Neu is coupled with dendritic cells and re-infused into the patient. This molecular structure of the fragment has been changed to boost the response of T lymphocytes to kill breast cancer cells.

In the clinical trial, which is supported by the Breast Cancer Research Foundation, patients will be randomized to receive either dendritic cells coupled to the engineered HER2/Neu fragment or a fragment of the non-engineered (normal) protein.

Dosages will vary, with patients receiving escalating doses of the dendritic cells during the trial.

The treatment consists of three 30-minute infusions three weeks apart. "We anticipate two years to complete the trial, that's based on enrolling 25 individuals," Dr. Serody said. "If you respond to the treatment, you may be eligible to continue treatment for long as you want."

"We're looking for clinical regression of established tumors. By definition, this means at least a 25 percent shrinkage of established tumors," Dr. Serody said.

Serody acknowledges that the engineered protein may prove no more effective than treatment with the standard protein. This is the reason for evaluating both treatments in the trial.

Why enroll in this clinical trial? "In the setting of metastatic disease, even if the disease is stable, very few are cured," the researcher said. Less than two percent of women with advanced breast disease survive ten years after diagnosis, according to recent data.

"We believe that the vaccine can be given safely. Our hope is that by using very sophisticated techniques to monitor for an ongoing immune response against the tumor we can determine if the vaccine has a benefit in the treatment of advanced breast cancer," Dr. Serody said.

To qualify for the UNC vaccine trial requires meeting the following criteria:

Patients will not know their tissue type and this will be evaluated prior to the collection of cells for treatment. In addition, participants cannot receive chemotherapy while in the trial, although previously treatment with chemotherapy is acceptable. Participants may receive hormonal therapy during the trial.

According to Serody, this vaccine trial also marks a first for UNC Lineberger: the translation of basic research to treatment totally in-house; that is, going from test-tube to mice to humans without collaboration outside of UNC.

"Our group made the altered compound, did all the pre-clinical work in animals and are now taking this to people," the researcher said. "This is how we envision doing things in the next millennium."

As to the vaccine's future, the UNC team hopes it will see more widespread use. "We're hoping that if it shows some benefit against metastatic disease that the vaccine treatment will eventually be used earlier, for instance after chemotherapy, as an alternative treatment for women at risk for metastatic breast cancer." Serody said.
-end-
By LESLIE H. LANG
UNC-CH School of Medicine

Women interested in enrolling in the trial can contact either Dr. Serody at 919-966-6975 or call Mary Myers in the Lineberger Cancer Center protocol office, 919-966-4432.

Note: Contact Dr. Serody at 919-966-6975, email: Jonathan_Serody@med.unc.edu

University of North Carolina Health Care

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.